Simbol NOVO-B | |
Simbol | NOVO-B |
Simbol eToro | NOVO-B.CO |
MarketWatch | NOVO-B |
Finviz | NOVO-B |
Yahoo Finance | NOVO-B.CO |
Google Finance | NOVO-B |
TradingView | NOVO_B |
Investing.com | NOVO-B |
Wikipedia | Novo Nordisk |
Denumire | Novo Nordisk B A/S |
Website | novonordisk.com |
Piața | CPH |
ISIN | DK0060534915 |
Sector | Health Technology |
Industrie | Pharmaceuticals Major |
Monedă | DKK |
Preț | 676,5500 DKK |
Capitalizare bursieră | 3.020,000 mld. DKK |
P/E | 40,44 |
Beta | 1,2501 |
Dividend | 1,05% |
EPS | 16,7664 |
Profit anual | +47,50% |
Dată actualizare | 18.12.2023 |
Descriere |
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark |
Data | P/E | Beta | Capitalizare | Dividend | EPS | Profit anual | Preț |
06.09.2021 | 32,84 | 1,0853 | 1.430,000 | 0,00% | 0,0000 | +52,74% | $0,00 |
16.02.2023 | 40,35 | 1,0757 | 2.230,000 | 1,28% | 24,5109 | +45,26% | $972,74 |
18.05.2023 | 42,47 | 1,1301 | 2.580,000 | 1,08% | 27,0764 | +56,67% | $1.150,47 |
04.08.2023 | 39,21 | 1,1447 | 2.380,000 | 1,17% | 27,0764 | +40,64% | $1.063,40 |
12.09.2023 | 22,82 | 1,1923 | 1.530,000 | 2,08% | 29,8605 | +71,41% | $681,50 |
18.12.2023 | 40,44 | 1,2501 | 3.020,000 | 1,05% | 16,7664 | +47,50% | $676,55 |